Indeed, in extracranial tumors, LAG-3 expression in melanoma was shown to be associated with better prognosis and response to immune checkpoint inhibitors [22]; however, further translational data from trials investigating LAG-3-blocking agents in solid tumors are needed. This evidence concerns the gene LAG3 and melanoma.